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Background: Remifentanil infusion is commonly used for general anesthesia but reflex cough can occur after an 
intravenous (IV) infusion. This study was designed to examine the effect of IV-dexamethasone on remifentanil-
induced cough (RIC).
Methods: One hundred thirty patients scheduled for elective surgery were randomly assigned into two groups that 
received by either 2 ml of IV 0.9% saline (Group C, n = 68) or 10 mg of dexamethasone (Group D, n = 62) 5 min before 
administration of remifentanil at a target effect-site concentration of 5 ng/ml. The incidence and severity of coughs of 
each patient were recorded.
Results: The overall incidence of cough was 6.5% (4/62 patients) in Group D and 26.5% (18/68 patients) in the Group 
C (P =  0.002). The severity of cough observed was significantly different by dexamethasone pretreatment (P =  0.02) 
but there were no significant hemodynamic changes.
Conclusions: Pretreatment with dexamethasone after IV administration was effective in suppressing the reflex cough 
induced by remifentanil infusion. (Korean J Anesthesiol 2011; 60: 403-407)
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Introduction
    Remifentanil is a fentanlyl derivative and a μ-opioid receptor 
agonist with a very short reaction time. It has been shown that 
during induction of general anesthesia, and tracheal intubation, 
opioids suppress the cough reflex. Similar to fentanyl, the 
injection of remifentanil induces cough (i.e. remifentanil-
induced cough, RIC), and the incidence has been reported to 
be approximately 27-28% [1,2]. 
    Cough induced during the induction of general anesthesia 
sometimes, elevates cerebral, ocular or abdominal pressure, 
and thus it may become threatening to the patients. Tweed and 
Dakin [3]. have reported the cases requiring immediate tracheal 
intubation for excessive coughs prior to the induction of general 
anesthesia.
    Until now, efforts have been made to reduce the cough reflex 404 www.ekja.org
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induced by opioids agonists, -and it has been reported that the 
selective β-2 agonist turbutaline or salbutamol, lidocaine, and 
ketamine were effective on reducing fentanyl-induced cough 
(FIC) or RIC [1,2,4-6]. In addition, Lim et al. [7] have reported 
that a split- dose intravenous injection of - remifentanil reduced 
the incidence of cough, and Lin et al. [8] have reported that the 
pretreatment with dexamethasone reduced FIC effectively.
    There are no studies on the incidence or severity of RIC 
in cases when patients are pretreated with the intravenous 
injection of dexamethasone. 
    Therefore, in our study, the incidence and severity of RIC 
was examined when patients were pretreated with 10 mg of 
dexamethasone, IV prior to the injection of remifentanil.
Materials and Methods
    This study was approved by the Institutional Review Board. 
The purpose and methods of the study were explained 
sufficiently to patients and their guardians and then, consent 
was obtained for the study. 
    The study was conducted on 140 patients between the age of 
18 years and 70 years with an Anesthesiologists Physical Status I 
and II.
    Patients with a past history of smoking, chronic obstructive 
lung diseases, asthma or upper respiratory infection, a history 
of angiotensin converting enzyme inhibitor, bronchodilators, 
or steroid uses, or the history of allergy to drugs were excluded 
from our study. The patients fasted for 8 hours prior to surgery. 
A 20 G cannula was installed on the dorsum manus prior 
to the arrival in the operation rooms, and a T-connector 
was connected for drug injection. Midazolam (2 mg) and 
glycopyrrolate (0.2 mg) were injected intramuscularly 30 
minutes prior to the induction of anesthesia.
    For all patients arriving in the operating room, an electro-
cardiomyogram, non-invasive blood pressure, and pulse 
oximetery were performde and the vital signs of patients 
were measured. A total of 140 patients were considered, 
but 10 patients dropped out and, 130 patients were then 
randomly assigned to either the control group (Group C) or 
the dexamethasone group (Group D). Five minutes prior to the 
injection of remifentanil, 10 mg of dexamethasone (in 2 ml total 
volume) was injected into patients in D group, and the same 
volume of 0.9% saline was injected into patients in group C. 
    Remifentanil was injected until the concentration reached 
the target concentration of 5 ng/ml using a Target- controlled 
infusion device (TCI) [Orchestra
Ⓡ with Base Primea, Fresenius-
Kabi, France]). Another anesthesiologist who does not know 
the type of drugs injected recorded whether or not cough 
developed as well as the frequency of cough from the time of 
the injection of remifentanil to 2 minutes after reaching the 
target concentration 5 ng/ml. Blood pressure of patient, pulse, 
and oxygen saturation levels were recorded immediately after 
arrival at operation room (T0), immediately after remifentanil 
reached the target concentration (T1), and after the injection of 
propofol (T2). The interval between T0 and T1 varied depending 
on the preparation process and the time to reach the target 
concentration for each patient: this time, was approximately 
5-10 minutes, and thus T2 was measured 5 minutes after the 
measurement of T1.
    The severity of cough was graded depending on the frequency 
of cough, and was recorded as mild (1-2 times), moderate 
(3-4 times), or severe (more than 5 times). A preliminary study 
was performed on 30 patients, and it was found that the cough 
reflex developed from the infusion of remifentanil to within 2 
minutes after reaching the target concentration 5 ng/ml). Based 
on this, 2 minutes after reaching the target concentration was 
determined as the time for the injection of propofol. 
    During the injection of remifentanil, if oxygen saturation level 
decreased to lower than 90%, mask ventilation support using 
100% oxygen was initiated immediately, and the development 
of apnea, stiffness of chest muscles, or neuropsychological 
symptoms were recorded. Apnea was defined as the respiration 
arrest period of longer than 20 seconds. Neuropsychological 
symptoms were defined as a the feeling of the dissociation 
phenomenon (i.e. as if the body is floating), impairment of 
alertness including drowsiness, changes of tastes, and changes 
of sensation such as numbness, hot, cold, etc..
    In preliminary studies, the incidence of cough in the 
dexamethasone group was reduced by approximately 20% when 
compared to the saline injected control group. Using these 
data,, the number of samples to obtain 80% statistical power at 
the 95% significance level was calculated as minimal 59 patients 
per group. Considering a drop out rate of approximately 10%, 
studies were attemped to be performed with a total sample 
number of 140 patients. For statistical analysis, SPSS 13.0 (SPSS 
Inc, Chicago, IL, USA) was used. All results were presented as a 
mean ± standard deviation. Comparison of age, height, weight, 
total amount of remifentanil, and hemodynamic measurements 
were analyzed by t-test. The comparison of the gender of the 
two groups, ASA class, with or without development of cough, 
and the severity of cough were analyzed by chi-square test. In 
all cases, a P value less than 0.05 was considered statistically 
significant.
Results
    Out of 140 patients; that entered the study, 10 patients; 
had blockage of the intravenous line and thus were excluded 
from the study. Hence, a total 130 patients were enrolled as 
study patients and 68 patients wererandomized in group 405 www.ekja.org
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C and , and the 62 patients were randomized into group D. 
In any patient during the injection of remifenils, there was 
never a development of the stiffness of chest muscles or 
neuropsychological symptoms and oxygen saturation level 
during the injection never decreased below 90%.
    When comparing demographic data of the patients in both 
groups, age, gender, height, weight and ASA class were not 
different. Similarly, the total injection volume of remifentanil to 
reach the target concentration of 5 ng/ml in the two groups was 
not different (Table 1). 
    The vital signs assessed at the three designated time points (T0; 
immediately after arriving at operation room, T1; immediately 
after reaching the target concentration of remifentanil, T2; 
after the injection of propofol) of the two groups were also not 
different. 
    The development of cough observed from the time of the 
injection of remifentanil in Group C occurred in 18 patients 
(26.5%). Among them, 7 patients (38.9%) were classified as mild 
(1-2 times), 7 patients (38.9%) were moderate (3-4 times), and 
4 patients (22.2%) were severe (more than 5 times). In Group D, 
cough  developed in 4 patients (6.5%). Among them, 2 patients 
(50%) were mild, 2 patients (50%) were moderate, severe cough 
was not observed. When compared to Group C, the incidence 
of cough in Group D was significantly lower, and similarly, the 
severity of cough was also significantly different (p < 0.05, Table 2).
Discussion
    In our study, IV pretreatment with 10 mg of dexamethasone 
prior to the injection of the targetconcentration of remifentanil; 
5 ng/ml; reduced the incidence of RIC from 26.5% to 6.5% 
(P < 0.05). In addition, in the group pretreated with 10 mg of 
dexamethasone, only mild or moderate levels of cough were 
noted, thereby significantly reducing the severity of cough when 
compared to Group C (p < 0.05).
    In comparison with fentanyl, the starting time for remifentanil 
after induction of general anesthesia is fast and regardless of the 
injection time of each -opioid agonists, their half-lives are short 
(approximately 3-5 minutes), and they rapidly reach steady 
state. If remifentanil is injected continuously in the induction of 
general anesthesia, reduced doses of propofol may be used.
    This could prevent the rapid decrease of blood pressure 
induced by propofol, avoid the rapid increase in blood pressure 
after response to stress such as tracheal intubation, therefore 
vital signs of patients could be more stable while induicing of 
general anehsthesia [9].
    It has been shown that cough develops in response to the 
administration of opioids, but the exact mechanisms have 
not been elucidated. However, opioid agents block the central 
sympathetic nervous system, activate the parasympathetic 
nervous system, and thus induce cough and the reflex contrac-
tion of the bronchus.
    Reports that the administration of bronchodilators sup-
pressed FIC support this possibility [4,5]. In addition, as another 
possible mechanism, the chemical reflex of the respiratory 
system mediated by fast acting irritant receptors located 
adjacent to the blood vessels in the respiratory system or vagal 
C-fibers receptors is also possible explanation [9]. Futher, it 
has been also reported that opioids contract tracheal smooth 
muscles resulting in the irritation of the stimulatory receptor in 
the mucosa of the upper respiratory tract [10,11].
    Kim et al. [1] have reported that to prevent RIC, a target 
remifentanil concentration of 4 ng/ml must be injected using 
a target infusion concentration device. When 0.5 mg/kg of 
Table 2.  The Incidence and Severity of Cough
Group Incidence
Severity of cough
 Mild Moderate Severe
Control (n = 68)
Dexamethasone (n = 62)
18/68 (26.5%)
4/62 (6.5%)*
7/18 (38.9%)
2/4 (50%)*
7/18 (38.9%)
2/4 (50%)*  
4/18 (22.2%)
0 (0%)* 
The values are shown as the number of patients (%). Control group: pretreated with saline fowolled by remifentanil infusion at a target effect 
site concentration of 5 ng/ml, Dexamethasone group: pretreated with 10 mg of dexamethasone and remifentanil infusion at a target effect site 
concentration of 5 ng/ml; Severity of cough: mild (1-2), moderate (3-4), and severe (5 or greater). *P < 0.05 compared with saline group.
Table 1.  Patients’- Characteristics and Total Remifentanil Dose
Group C (n = 68) Group D (n = 62)
Sex (M/F)
ASA physical status (I/II)
Age (yr)
Height (cm)
Weight (kg)
Total remifentanil dose (μg)
  25/43
  58/10
  41.1 ± 14.5
 163.9 ± 8.9
  60.8 ± 9.8
  81.3 ± 14.4
36/26
 54/8
 39.9 ± 14.3
164.6 ± 9.8
 63.8 ± 11.5
 84.7 ± 14.7
Values are mean ± SD or number of patients. Group C: pretreated 
with saline followed by remifentanil infusion at a target effect 
site concentration of 5 ng/ml, Group D: pretreated with 10 mg of 
dexamethasone followed by remifentanil infusion at a target effect 
site concentration of 5 ng/ml. Total remifentanil dose: Amount of 
infused remifentanil used until target effect site concentration of 5 
ng/ml. There was no significant difference in any parameter between 
the groups. 406 www.ekja.org
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lidocaine was injected prior to the injection, the incidence of 
cough was reduced from 27.6% to 15.2%. Kim et al. [2] have 
reported that when a target concentration of remifentanil was 
5 ng/ml, a prior injection of, 0.1 mg/kg of ketamine resulted in 
reduction in the development of cough from 27.9% to 11.5%. 
    In addition, Lim et al. [7] -have reported when a split -dose 
remifentanil was injected, the development of cough was 
reduced from 34% to 12%. Similarly, in our study, when 
remifentanil was injected in the control group, the development 
of cough was 26.5%, with comparable in incidence to the 
previous reports. In the group pretreated with 10 mg of 
dexamethasone, the development of cough was greatly reduced 
to 6.5%, and the severity of cough was also significantly lowered. 
    Dexamethasone has been used as a mast cell stabilizer. Murlas 
et al. [12] have reported that in guinea pigs, dexamethasone 
improves bronchoconstriction mediated by tachykinin. 
    Tachykinin is released after the activation of C-fibers in the 
airway and directly induces the contraction of smooth muscle 
in the airway [13]. Indirectly, it induces the release of histamine 
from mast cell in the airway and thus facilitates the excitation of 
receptors where histamine rapidly acts [14]. 
    In addition, it has been reported that dexamethasone enhances 
the activation of neutral endopeptidase which reverses the 
enhanced airway reactivity of airway epithelial cells [15,16]. 
Further, corticosteroids have been reported to increase beta 
adrenergic receptors on lung cells [17]. 
    It has been reported that dexamethasone injected once 
prior to surgery cough could prevent nausea and vomiting 
that may be developed after surgery [18], was effective on 
the amelioration of pain after surgery [19] and could reduce 
cough, which was the aim of this study. In addition, it has 
been reported that steroids reduce postoperative edema in 
numerous types of surgery. For example, Weber and Griffin 
[20] have reported that in patients scheduled for maxillofacial 
surgery, dexamethasone injected prior to surgery significantly 
reduced post-operative edema. On the other hand, long-term 
administration of steroid mediates immune suppressive effects, 
and thus it can increase the possibility of postsurgical infection, 
weaken the skin thus inducing iatrogenic Cushing’s syndrome, 
and decreases bone density [21]. Studies on the side effects of 
dexamethasone administered prior to surgery have not yet been 
reported.
    Henzi et al. [22] have reported that in healthy patients, adverse 
effects of the injection of 8-10 mg of dexamethasone once for 
the prevention of nausea and vomiting prior to surgery was not 
proven. The dose of dexamethasone frequently used to prevent 
nausea and vomiting associated with surgery is 5-10 mg for 
adults. In our study, 10 mg of dexamethasone was administered.
    A limitation of our study was that 10 mg of dexamethasone 
was administered regardless of the weight of patient, and thus 
studies on a more exact dose (i.e. based on mg/kg) of individual 
patients are required.
    In conclusion, pretreatment with 10 mg of dexamethasone 
prior to the injection of remifentanil suppressed  the develop-
ment and severity of cough induced by remifentanil without 
significant adverse effects. 
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